International Journal of Research in AYUSH and Pharmaceutical Sciences

Research Article

A COMPARATIVE CLINICAL EVALUATION OF *AMRITADYA GUGGULU* WITH AND WITHOUT YAVAMALAKI CHOORNA IN THE MANAGEMENT OF DYSLIPIDEMIA

Komala A¹, Santosh V R^{2*}

*1Assistant Professor, Department of Kayachikitsa, *2Assistant Professor, Department of Dravyaguna, JSS Ayurveda Medical College, Mysore, India.

ARTICLE INFO

Article history: Received: Jan 01, 2022 Revised: Jan 24, 2022 Accepted: Feb 14, 2022

Keywords: Medoroga, Dyslipidemia, Hyperlipidaemia, Prameha, Cholesterol, Apatarpana, Amritadya Guggulu, Yava Amalaki Churna.

ABSTRACT

As a result of confronting challenges of modernization, man has adapted himself to the fast paced life by modifying his dietary and lifestyle preferences to suit the modern era. This has resulted in a state of discrepancy between the external environment and his internal mechanism causing multitudes of diseases which referred as "lifestyle diseases". Dyslipidemia is a condition in which the level of lipoproteins (cholesterol, triglycerides or both) is raised in the plasma. For this "Amritadya Guggulu" mentioned in Chakradatta and "Yava Amalaki Choorna" mentioned in Charaka sutra sthana is selected. The ingredients of Amritadya Guggulu like Guduchi, Truti, Vella, Vatsaka, Triphala are Medohara and Tiktarasa pradhana which is Kapha vata hara, Laghu, Kapha shoshaka effective in case of Dyslipidemia on the other hand Yava Amalaki choorna is also having Medohara property. In the present study, 40 patients of Dyslipidemia were registered and were randomly placed and observed in two groups, treated with Amritadya *Guggulu* and *Amritadya Guggulu* with *Yavamalaki Choorna* for 30 days. Each disease feature was scored according to the assessment criteria and each patient was assessed and scored with respect to his/her presenting complaints. Respective scores were subjected for statistical analysis using paired student 't' test for the individuals groups and unpaired student 't' test to compare both the groups.

INTRODUCTION

In today's era lifestyle disorders such as dyslipidemia, obesity, diabetes mellitus, atherosclerosis, coronary artery disease, cerebro vascular accident are more common due to the change in the food habits and the standard of living. These are the major burning problems now days the population are facing.^[1]

 Access this article online

 Quick Response Code
 https://doi.org/10.47070/ijraps.v5i10.117

 Published by Mahadev Publications (Regd.)
 publication licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)

Dyslipidemia is defined as abnormal amount of lipids (eg: cholesterol and /or fat) in the blood. In developed countries most dyslipidemias are Hyperlipidaemia; that is, an elevation of lipids in the blood. Cardio vascular disease remains the number one cause of mortality and morbidity that is due to the common risk factors such as Dyslipidemia and Hypertension.^[2]

Total cholesterol increase on the average more than 2mg/Dl per year during early adulthood and continuously increasing. Men 45 years or older and women aged 55 years or older are considered to be have age as a risk factor. In the world wide review, according to W.H.O over all raised cholesterol is estimated to cause 2.6 million deaths of 45% total population and 29.7 million disability.^[3]

Abnormal cholesterol levels are estimated to cause 18% of the global CVDs and 56% of the global Ischemic Heart Disease (IHD). For every 1% reduction in lipid level, the risk of heart disease reduces by 2.5%. Dyslipidemia is an established risk factor for atherosclerotic disease^[4]. The causes of cardiovascular disorders are multi factorial. Some of these factors related to lifestyles, such as tobacco, smoking, lack of physical activity and dietary habits are thus modifiable. Other modifiable risk factors are elevated blood pressure, Type 2 diabetes. dyslipidemias and non-modifiable factors are age and male gender^[5].

According to Ayurveda Dyslipidemia can be corelated to raise 'Meda' in the body. In Ayurvedic classics, various scholars have tried to use distinct nomenclature for the same like *Rasaqata Sneha* Vriddi, Rasa Rakta gata Sneha Vriddi, Medovriddhi, Medoroga or Medo dosha. Sthoulva. Ama Medo Dhatu etc. Attempts were made by various Acharyas stated under broad umbrella of Santarpanajanya vyadhis. If we look into Ayurvedic perspective, it becomes clear that Kapha (Kledaka), Vata (Samana & Vyana) Meda (fat/lipids) & *Medodhatwaani* are involved in the pathogenesis of Medoroga (Dyslipidemia).

In Ayurvedic classics there are a number of herbal and herbo-mineral compounds for the management of Dyslipidemia. Although a number of research works have been done on management of Dyslipidemia, still more formulations should be tried for the effective management of this dreadful disease. For this "Amritadya Guggulu" mentioned in "Yava Chakradatta^[6] and Amalaki choorna" mentioned in *Charaka sutra sthana*^[7] are selected. The ingredients of Amritadya Guggulu like Guduchi, Truti, Vella, Vatsaka, Triphala are Medohara and Tiktarasa pradhana which is Kapha vata hara, Laghu, *Shleshma upashoshaka* effective in case of dyslipidemia on the other hand Yava Amalaki choorna is also having medohara property.

OBJECTIVES

- 1. To evaluate the efficacy of *Amritadya Guggulu* in management of Dyslipidemia.
- 2. To evaluate the comprehensive effect of Amritadya Guggulu and Yava Amalaki Choorna in **Demographic data**

Age

the management of Dyslipidemia.

3. To compare the effect of *Amritadya Guggulu* with and without Yava Amalaki Choorna in the management of Dyslipidemia.

Methodology

For the present study 55 patients of either sex of age group 30-70 yrs and diagnosed as Dyslipidemia is selected. The patient will be selected strictly abiding to the inclusion and exclusion criteria. The patients thus selected will be randomly grouped into two group of size each 20. The first group will be administered "Amritadya Guggulu" 500mg 2 tablets twice daily before food (morning and night) and the duration of the treatment will be 30 days. The second group will be administered "Amritadva Gugaulu" same as in first group with "Yavamalaki Choorna" for 30davs.

Inclusion Criteria

- 1. The age groups of 30-70 years were selected because Madhyama vava is said to be the most active phase of the life with lots of physical and mental stress, incompatibility in dietary habits which can trigger the disease.
- 2. Patients presenting with elevated lipid profile values and decreased HDL values are included.
- 3. There is no hard and fast rule that all the Dyslipidemia patients are obese. So the patients with or without obesity were included, to analyze the effect of therapy on weight and BMI

Exclusion Criteria

- 1. Patients who have received anti cholesterol medication within last 8 weeks were excluded from the study in order to avoid the counter action of drug
- 2. Uncontrolled and metabolic disorders other than Dyslipidemia were excluded because the patient having cardiovascular disease and hypertension may need emergency treatment.

Observations

The analyses of observation of clinical study were done by using the appropriate statistical data. The observations documented during the present study with respect to demographic data, clinical data were present in the tables.

Age in	No. of patients						
years	Group 1	Group 2	Total	Percentage			
30-40	4	3	7	17.5%			
40-50	8	6	14	35%			
50-60	5	9	14	35%			
60-70	3	2	5	12.5%			
IIRADS	IIRAPS October 2021 Vol 5 Issue 10						

Table 1. Age wise distribution of nationts

Komala A, Santosh V R. Amritadya Guggulu With and Without Yavamalaki Choorna in The Management of Dyslipidemia

In the study maximum patients were seen in the age group 40-60 years

Table 2: Sex wise distributions of patients

Sex	No of patients		Total	Percentage
	Group 1	Group 2		
Male	14	13	27	67.5%
Female	6	7	13	32.5%

In this study maximum patients were male (67.5%), rest (32.5%) were females.

Table 3: Religion wise Distribution of Patients

Religion	No of patients		Total	Percentage
	Group1	Group 2		
Hindu	2	4	6	15%
Muslim	10	6	16	40%
Christian	8	18	18	45%

In this study shows that among 40 patients, maximum number of patients belongs to Christian religion (45%) and Muslim religion (40%), minimum number of patients belongs to Hindu religion (15%). **Marital Status**

Table 4: Marital status wise distribution of patients

Marital status	No of patients		Total	Percentage
	Group 1	Group 2		
Married	19	18	37	92.5%
Unmarried	1	2	3	12.5%

In the study among 40 patients, 37 patients (92.5%) were married and 3 patients (12.5%) were unmarried. **Educational Status**

Educated	No of patients		Total	Percentage
	Group1	Group2		
Uneducated	0	1	1	2.5%
Primary school	1	1	2	5%
Middle School	2	0	2	5%
High school	2	3	5	12.5%
Graduate	8	10	18	45%
Post graduate	7	5	12	30%

Table 5: Education wise Distribution of Patients

In this study maximum number of patients was graduates (45%) **Socio Economic Status**

Table 6: Socio economic Distribution of Patients

Socio economic status	No of patients			
	Group1	Group2	Total	Percentage
Poor-lower middle class	3	1	4	10%
Middle class	8	7	15	37.5%
Upper middle class	9	12	21	52.5%

In this study, maximum patients (52.5%) were upper middle class.

Occupation

Occupation	No of pa	No of patients		Percentage
	Group1	Group2		
House wife	4	5	9	22.5%
Business	10	8	18	45%
Carpenter	1	0	1	2.5%
Teacher	2	3	5	12.5%
Banker	1	1	2	5%
Engineer	2	3	5	12.5%

Table 7: Occupation wise Distribution of Patients

In this study maximum number of patients (45%) were in business. **Nature of Work**

Table 8: Nature of Work wise Distribution of Patients

Nature of work	No of	No of patients		Percentage
	Group1	Group 2		
Sedentary	14	12	26	65%
Physical stress	4	4	8	20%
Mental stress	2	4	6	15%

In this study, maximum number (65%) of patients had sedentary nature of work. **Addictions**

Table 9: Addiction wise Distribution of Patients

Addiction	No of patients		Total	Percentage
	Group1	Group2		
Tea and Coffee	7	10	17	42.5%
Alcohol	11	8	19	47.5%
No addictions	2	1	3	7.5%

Diet

Table 10: Diet wise Distribution of Patients

Diet	No of	No of patients		Percentage
	Group1	Group2		
Mixed	16	13	29	72.5%
Vegetarian	4	7	11	27.5%

In this study, maximum number of patients (72.5%), had mixed diet Observation Based on Lipid Profile Values Total Cholesterol

Table 11: Distribution as per Total Cholesterol

Range	No of patients		Total	Percentage
	Group 1	Group 2		
120-180	0	2	2	5%
181-240	13	7	20	50%
>240	7	11	18	45%

In this study maximum number (50%), patients had total cholesterol between 181-240mg/dl

LDL

Range	No of patients		Total	Percentage
	Group1	Group2		
100-160	14	8	22	55%
>160	6	12	18	45%

Table 12: Distribution as per LDL level

In this study maximum number of patients (55%), had LDL Cholesterol level between 100-160mg/dl. **HDL**

	Table 13: Distribution as per HDL											
Range	No of	patients	Total	Percentage								
	Group1	Group2										
<40	2	3	5	12.5%								
40-60	16	16	32	80%								
>60	2	1	3	7.5%								

In this study 12.5% patients had HDL below 40mg/dl, 80% patients had HDL between 40-60 mg/dl and rest 7.5% had HDL above 60mg/dl. **VLDL**

Table 14: Distribution as per VLDL

Range	No of patients		Total	Percentage
	Group1	Group2		
5-30	2	1	3	7.5%
>30	18	19	37	92.5%

In this study maximum number of patients (92.5%) had VLDL range above 30mg/dl **Triglycerides**

Table 15: Distribution as per Triglycerides


Range	No of	No of patients		Percentage
	Group1	Group1 Group2		
<150	4	3	7	17.5%
151-240	12	15	27	67.5%
>240	4	2	6	15%

In this study maximum number of patients (67.5%) had Triglycerides between 151-240mg/dl, 15% patients had Triglycerides below 150mg/dl and 15% patients had triglycerides above 240 mg/dl.

Table 16: Lakshanas wise Distribution of Patients

Lakshanas	No. of	Patients	Total	Percentage
	Group 1	Group 2		
Chalatva of sphik	18	16	34	85%
Chalatva of udara	17	15	32	80%
Chalatva of sthana	2	0	2	5%
Anutsaha	15	13	28	70%
Krichra vyavaya	2	1	3	7.5%
Dourbalya	10	17	27	67.5%
Dourgandhya	7	9	16	40%
Swedaavabhaada	9	10	19	47.5%
Kshudaatimaatra	0	7	7	17.5%
Pipaasaatiyoga	0	0	0	0

Graph 15: Lakshanas wise Distribution of Patients



In this study, maximum numbers of patients (85%) have *Chalatva* of *Sphik*. **RESULTS**

Effect of treatment

In the present study, 40 patients of Dyslipidemia were registered and treated with *Amritadya Guggulu* and *Amritadya Guggulu* with *Yavamalaki Choorna* for 30 days. Each disease feature was scored according to the assessment criteria and each patient was assessed and scored with respect to his/her presenting complaints. Respective scores were subjected for statistical analysis using paired student 't' test for the individuals groups and unpaired student 't' test to compare both the groups. Following are the obtained result data of both the groups.

Lipid	Mean s	Mean score Dif		%	S.D±	Т	р	Remarks
value	BT	AT	in mean	improvement	S.E	value		
S. Chol	235.65	185.75	49.90	21.17	17.19±3.84	12.98	< 0.001	H.S
LDL	147.15	115.30	31.85	21.64	23.07±5.16	6.172	< 0.001	H.S
HDL	48.8	49.95	1.15	2.35	2.36±0.53	2.17	0.043	S
VLDL	36.7	33.2	3.5	9.53	2.89± 0.64	5.41	< 0.001	H.S
TGL	186.7	150.75	35.95	19.2	25.19±5.63	6.380	< 0.001	HS

Table 17: Effect on lipid profile of Group 1

The above table illustrates that, In Group 1 S. Cholesterol was reduced 21.17% after 30 days of treatment, LDL was reduced by 21.64%, VLDL was reduced by 9.53%, S. Triglycerides were reduced by 19.2% which were all statistically significant at p<0.001 and HDL was increased by 2.35%. There is a statistically significant change in HDL (P=0.043).

Table 18: Effect on lipid profile Group 2

					-			
Lipid	Mean	score	Difference in	%	S.D±S.E	T value	р	Remarks
value	BT	AT	mean	improvement				
S. Chol	237.7	181.1	56.6	23.8	23.71±5.30	10.67	< 0.001	H.S
LDL	160.4	124.8	35.55	22.1	20.22±4.52	7.86	< 0.001	H.S
HDL	47.45	50.15	2.7	3.49	3.09±0.69	-3.89	< 0.001	HS
VLDL	38.75	32.35	6.4	16.51	4.60± 1.03	6.21	< 0.001	H.S
TGL	191.15	142.9	48.25	25.2	21.969±4.91	9.82	< 0.001	HS

The above table illustrates that, S. Cholesterol was reduced 23.71%, LDL was reduced by 22.1%, VLDL was reduced by 16.5%, S. Triglycerides were reduced by 25.2 % and HDL was increased by 3.49% which were all statistically significant at p<0.001.

Komala A, Santosh V R. Amritadya Guggulu With and Without Yavamalaki Choorna in The Management of Dyslipidemia

Effect on weight and BMI

	Mean score		Mean score		Mean score		Mean score		Mean score		Mean score		Mean score		Mean score		Mean score		Mean score		Mean score		Mean score		Mean score		Χ	% IMP	S.D± S.E	t-	р	Remarks
	BT	AT				value																										
Weight	70.32	70.1	0.225	0.31	0.69± 0.15	1.44	0.165	NS																								
BMI	25.29	25.22	0.071	0.28	0.22±0.050	1.39	0.17	NS																								

Table 19: Effect on weight & BMI in Group 1

In Group1, this table indicates 0.31% reduction in weight and 0.28% reduction in BMI, both are not statistically significant at p =0.165 and p=0.17.

Table 20: Effect on weight & BMI in Group 2

	Mean score		Mean score		Mean score		X	% IMP	S.D±S.E	t-value	р	Remarks
	BT	AT										
Weight	75.65	75.15	0.5	0.66	0.79± 0.17	3.247	0.011	S				
BMI	26.98	26.80	0.18	0.66	0.28±0.063	2.85	0.010	S				

In Group 2, this table indicates 0.66% reduction in weight and 0.66% reduction in BMI, both are statistically significant at p = 0.011 and p = 0.010.

Effect of treatment between Group 1 and Group 2

Table 21: Effect on Lipid profile in both Groups (Unpaired t Test)

Parameter		Group 1		Group 2			t	Р	Remarks
	Mean	SD	SE	Mean	SD	SE			
Total Cholesterol	49.9	17.19	3.84	56.6	23.71	5.3	0.034	0.97	NS
LDL	31.85	23.07	5.16	35.55	20.22	4.52	-0.14	0.88	NS
VLDL	3.5	2.89	0.64	6.4	4.6	1.03	-2.67	0.01	S
TG	35.95	25.19	5.63	48.25	21.96	4.91	-1.64	0.1	NS

This table indicates there is no significant difference between two groups except VLDL (P=0.01)

Table 22: Effect on HDL in both the Groups

Parameter	Group 1			Group 2			t	р	Remarks
	Mean	SD	SE	Mean	SD	SE			
HDL	-1.15	2.36	0.530	-2.7	3.09	0.69	1.58	0.12	NS

The difference in the mean values of the two groups is not great enough to reject the possibility that the difference is due to random sampling variability. There is not a statistically significant difference between the input groups (P = 0.122).

Table 23: Effect on BMI and Weight in both the Groups


Parameter	Group 1			Group 2			t	р	Remarks
	Mean	SD	SE	Mean	SD	SE			
BMI	0.12	0.20	0.04	0.18	0.29	0.06	-0.78	0.43	NS
Weight	0.37	0.74	0.14	0.54	.84	0.188	-0.74	0.48	NS

There is a no statistically significant difference between BMI of the input groups (P = 0.43) and Weight of two groups (P = 0.48).

Overall Result

T	Table 24: Overall result									
Improvement		No. of patients								
	Group 1	Group 2	Total							
Marked (>50%)	0	0	0	0						
Moderate (>25%)	3	5	8	20%						
Mild (<25%)	17	15	32	80%						
No change (0%)	0	0	0	0						

Graph 1: Overall Result



DISCUSSION

The following Table no-25 depicts the efficacy of medications on lipid profile parameters and other factors of among two groups.

Lipid profile Parameters	Efficacy
Total cholesterol	In Group 1, 21.17% reduction was observed in Total Cholesterol while 23.8% reduction was observed in Group 2. Both the results were statistically significant (P<0.001). The percentage of relief was more in Group 2.
S. LDL	Reduction observed in S.LDL was 21.6% in Group 1 while 22.1% reduction was observed in Group 2. Both the results were statistically significant (P<0.001). Thus, Group 2 provided little better result in reduction of S.LDL
S. HDL	S.HDL level was increased up to 2.35% in Group 1while in Group 2 by 3.49%. Both the results were statistically significant in Group 1 (P=0.043) and Group 2 (P<0.001). But percentage relief was more in Group 2.
S. VLDL	In Group 1, there was 9.35% reduction in S.VLDL while 16.51% reduction was found in Group and both the results were statistically significant (P<0.001). But the percentage of relief was more in Group 1.
S. Triglyceride	S. Triglyceride reduced by 19.2% in Group 1, whereas 25.2% reduction was observed in Group 2. Both the results were statistically significant (P<0.001). However the percentage of relief was more in Group 2.
Weight	In Group 1 there was only 0.31% reduction which is statistically insignificant (p=0.165) while in Group 2 there was 2.20% reduction which is statistically significant (p=0.004). But percentage relief was more in Group 2.
BMI	In Group 1, 0.53% reduction which is statistically significant ($p=0.027$) while in Group 2 there was 2.14% reduction which is statistically significant ($p=0.002$). But percentage of relief was more in Group 2.
Sthoulya lakshanas	After the 30 days of treatment, <i>Amritadya Guggulu</i> in Group 1 and <i>Amritadya Guggulu</i> with <i>Yavamalaki Choorna</i> in Group 2 have not produced appreciable changes in the <i>Lakshanas</i> of <i>Medoroga</i>

Komala A, Santosh V R. Amritadya Guggulu With and Without Yavamalaki Choorna in The Management of Dyslipidemia

Mode of action of Amritadya Guggulu

Amritadya Guggulu is an Oushada yoga explained under Chakradatta Sthoulva adhikara. It contains Amrutha (Guduchi), Truti (Ela), Vella (Vidanga), Vatsaka (Kutaja Twak), Kali (Vibhitaki), Pathya (Haritaki), Amalaki and Guggulu in increasing quantity. As the drugs are mixed in an increasing order, thus the highest ingredient being *Guagulu* which is best Vata and Medohara^[8]. Dyslipidemia if seen through the lens of Ayurveda may be taken as Medo roga or Medo dosha, as Bahu abaddha medas which circulates all over the body. *Tikta katu*, Kashaya rasas will cause Medo vilayana. The drugs such as Guggulu, Haritaki, Vibhitaki, Vidanga, and Guduchi are Rooksha, Sookshma and Ushna in nature thus penetrating into the deeper channels and removing Sanga/obstruction.

In case of Hyperlipidaemia, obstruction may be seen as atherosclerosis seen due to deposition of fat in arteries. Hence by the virtue of above properties, it helps in liquefaction of these fatty blockages. Drugs such as *Amalaki, Ela,* and *Kutaja* by virtue of their *Sheeta veerya,* pacifies the *Theekshnagni.*

Haritaki is 3rd highest dose amongst the ingredients, which is *Kashaya rasa pradhana* and best *Vatanulomana*^[9].

Discussion on Mode of Action of Yavamalaki Churna

The combination of *Yava* and *Amalaki* acts on basis of principle "*Guru Cha Apatarpana*" ^[10].

The drug *Yava* is having the properties like *Madhura*, *Ruksha*, *Sheeta* and *Guru* gunas which helps in correcting the pathogenesis of *Medodushti*. The *Sheeta veerya* of the drug causes satiation by balancing the aggravated *Agni*. *Yava* is best drug in "*Purisha janana*" ^[11] (more production and increasing the bulkiness of fecal matter). It shows the drug increases the quantity of faeces by eliminating excess of fat and faeces is the only route to eliminate lipid from the body.

The action of *Yava* can be explained in the terms of modern science as follows. The barley is rich in fiber and constitutes around 3.9% of the drug. Barley which is rich in water soluble fiber and body needs this type of fiber. Even wheat is rich in fiber but that is not rich in water soluble fiber. The functions attributed to water soluble fiber are many in number. Few of them are explained here. The fiber increases the gastric emptying time by taking long duration to get partly digested. There by it initiates the satiety centre located in hypothalamus and reduces the food intake. Even its movement through the intestines is sluggish. It hinders the absorption through the villi thereby reducing the energy uptake. It mainly affects

the absorption of fat, as the fat is having high molecular weight. It also affects the enteric reabsorption of cholesterol there by reducing the cholesterol level and initiates the movement of stored fat. All these actions bring about increased gastric emptying time, excess utilization of energy, mobilization of stored fat for the purpose of utilization, hampered re-absorption of enteric cholesterol and fat.

Classics have dealt Amalaki as Pitta pradhana Tridosha shamaka. Pitta and Agni are interrelated; hence this action of the drug controls derangement of both Agni and Tridosha. Till recent days it was believed that the different actions of the drug are due to its rich vitamin C content. But now it is established that the different types of tannins present in it is responsible for its multi-factorial action. These tannins are said to be useful in maintenance of micronutrient level in the body system. Thus it gives strength but does not yield energy i.e., it helps in the utilization of stored energy. The Lavana varjita Pancha rasa may be responsible for good actions as Sarva rasa sevana results health. The Sheeta Virya pacifies Agni thereby inducing satiety. Thus the combined action of all the properties of the drug is responsible for its beneficiary effects.

Thus the combination of drug will have property of guru i.e., takes long duration for complete metabolism and *Apatarpana* i.e., will not nourish by means of calories.

CONCLUSION

The causes of elevated lipid profile are mainly uncontrolled erratic diet, supplemented with lack of exercises. i.e., increased input of energy with decreased energy output. Hyperlipidaemia in Ayurvedic literature is explained in bits and fragments under the broad umbrella of *Sthoulya-Medoroga-Prameha*.

As it is a *Santarpanottha vikara*, hence the ideal management protocol is *Rookshana*. *Amritadya Guggulu* has given significant result on elevated lipid profile. *"Guru Cha Apatarpana"* principle plays an important role in *Medoroga* management in reducing its symptoms by *Vighatana* of its *Samprapti*. So in Group 2 *Yavamalaki Choorna* is taken along with *Amritadya Guggulu*.

Both the groups (1 and 2) showed reduction in serum T. cholesterol, T.G., LDL, VLDL and statistically significant increase in HDL levels. In both groups there was reduction in body weight and BMI, but compare to group 1, in group 2 good weight loss was observed. *Amritadya Guggulu* and *Yavamalaki Choorna* however did not produce any significant change in *Lakshanas*, which were ascertained before

and after the study. The reason could well be, short study duration of 30 days which was taken and gross physical changes in body in reality is difficult. Hence by this study, it can be claimed that *Amritadya Guggulu* has significant effect on elevated lipid profile and if along with *Yava Amalaki choorna* it shows more effect.

REFERENCES

- 1. Dorland's pocket Medical dictionary 28th Edition, pgno:271
- Dr.Ajay Gopalani G & Dr.Bhushan A Sarmandal's, Obesity, Kottakkal Ayurveda Series- 67, 1st Edition
- 3. www.who.int
- 4. American Heart Association Nutrition Committee Circulation 2006; 114: 82-96.
- 5. European Heart Journal (2011) Guidelines for the Management of Dyslipidemias. P.No:1773.
- 6. Acharya Chakrapanidatta-Chakradutta, Sthoulya chikitsa 36th chapter, 18th shloka, Choukhambha Orientalia, Varanasi, 2002, page 222
- 7. Acharya charaka-charaka samhitha, English translation by R.K.Sharma & Vaidya Bhagwan

Cite this article as:

Komala A, Santosh V R. A Comparative Clinical Evaluation of Amritadya Guggulu With and Without Yavamalaki Choorna in The Management of Dyslipidemia. International Journal of Research in AYUSH and Pharmaceutical Sciences, 2021;5(10):581-590. https://doi.org/10.47070/ijraps.v5i10.117 Source of support: Nil. Conflict of interest: None Declared

Dash, edition reprint 2009, Chowkamba Krishnadas academy, Varanasi. Sutrasthana 21/23, Page No.303

- 8. Acharya Vagbhata, Ashtanga Sangraha, Editor-Dr Bramhanand Tripathi, 2009 edition, Chaukhambha Sanskrit Pratishthan, Varanasi, Sutrasthana 13.
- Bhavamishra, Bhavaprakasha Nighantu, Commentary by Dr.K.C.Chunekar & edited by Dr. G.S. Pandey, Reprint 1998, Chowkamba Bharathi academy, Varanasi, Haritakyadi varga 20, Page no-5
- Acharya charaka-charaka samhitha, English translation by R.K.Sharma & Vaidya Bhagwan Dash, edition reprint 2009, Chowkamba Krishnadas academy, Varanasi. Sutrasthana 21/20, Page No.303
- 11. Acharya charaka-charaka samhitha, English translation by R.K.Sharma & Vaidya Bhagwan Dash, edition reprint 2009, Chowkamba Krishnadas academy, Varanasi. Sutrasthana 25/40, Page No.468.

*Address for correspondence Dr. Santosh V R Assistant Professor, Department of Dravyaguna, JSS Ayurveda Medical College, Mysore. Email: dr.santoshveda@gmail.com Contact: 9591689628

Disclaimer: IJRAPS is solely owned by Mahadev Publications - A non-profit publications, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IJRAPS cannot accept any responsibility or liability for the articles content which are published. The views expressed in articles by our contributing authors are not necessarily those of IJRAPS editor or editorial board members.